Profile data is unavailable for this security.
About the company
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
- Revenue in USD (TTM)75.67m
- Net income in USD-31.15m
- Incorporated2010
- Employees132.00
- LocationOptiNose Inc777 Township Line Road, Suite 300YARDLEY 19067United StatesUSA
- Phone+1 (267) 364-3500
- Fax+1 (302) 636-5454
- Websitehttps://www.optinose.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 45.14m | 100.00 | -- | -- | -- | 4.90 | -1.83 | -1.83 | 0.1979 | -0.7467 | 0.1416 | 1.67 | 4.67 | 92,100.00 | -130.68 | -55.75 | -174.03 | -78.33 | 74.08 | -- | -922.81 | -754.94 | 1.22 | -10.16 | 3.82 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| SCYNEXIS Inc | 8.57m | -36.44m | 45.16m | 29.00 | -- | 0.7715 | -- | 5.27 | -0.756 | -0.756 | 0.177 | 1.54 | 0.0692 | -- | 3.61 | 295,379.30 | -29.44 | -30.02 | -35.54 | -36.35 | -71.42 | -- | -425.41 | -86.76 | -- | -- | 0.1843 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -21.89m | 46.12m | 14.00 | -- | 2.63 | -- | -- | -0.8536 | -0.8536 | 0.00 | 0.6387 | 0.00 | -- | -- | 0.00 | -92.58 | -- | -114.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 49.87m | 137.00 | -- | 1,839.01 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| BGM Group Ltd | 29.87m | -7.86m | 50.59m | 298.00 | -- | 1.15 | -- | 1.69 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Aadi Bioscience Inc | 25.07m | -61.69m | 56.20m | 53.00 | -- | 0.8149 | -- | 2.24 | -2.29 | -2.29 | 0.9285 | 2.80 | 0.2225 | 0.696 | 4.09 | 281,685.40 | -54.75 | -50.25 | -65.27 | -56.15 | 87.39 | -- | -246.06 | -473.97 | 4.54 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| bluebird bio Inc | 53.12m | -300.52m | 57.77m | 375.00 | -- | -- | -- | 1.09 | -1.84 | -1.84 | 0.3039 | -0.0298 | 0.0985 | 2.03 | 4.42 | 141,653.30 | -55.72 | -34.75 | -96.37 | -40.84 | -43.49 | -124.35 | -565.74 | -5,770.41 | 0.3272 | -13.37 | 1.03 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| OptiNose Inc | 75.67m | -31.15m | 59.56m | 132.00 | -- | -- | -- | 0.787 | -0.2216 | -0.2216 | 0.5416 | -0.2725 | 0.6512 | 0.7659 | 2.96 | 573,272.80 | -26.80 | -48.25 | -- | -98.95 | 90.21 | 86.96 | -41.16 | -131.66 | 0.7198 | -1.61 | 1.48 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Cellectar Biosciences Inc | 0.00 | -49.67m | 64.10m | 20.00 | -- | 41.37 | -- | -- | -1.67 | -1.67 | 0.00 | 0.4079 | 0.00 | -- | -- | 0.00 | -168.84 | -83.69 | -450.38 | -99.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Hongchang International Co Ltd | 5.42m | -208.79k | 66.15m | 8.00 | -- | 1.63 | -- | 12.21 | -0.0004 | -0.0004 | 0.0104 | 0.0784 | 0.0991 | 5.50 | 37.20 | -- | -0.2731 | -7.98 | -0.2965 | -10.94 | 4.51 | 11.47 | -2.76 | -64.88 | 4.64 | -- | 0.3169 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 67.19m | 217.00 | -- | 0.4959 | -- | 21.13 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 22.06m | -30.97m | 70.36m | 176.00 | -- | 5.08 | -- | 3.19 | -2.23 | -2.23 | 1.59 | 1.03 | 0.32 | 0.9265 | 2.03 | 125,312.50 | -43.04 | -34.75 | -66.19 | -46.91 | 54.31 | 55.98 | -134.50 | -153.72 | 2.32 | -- | 0.58 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 98.92m | -1.24m | 71.10m | 237.00 | -- | 2.44 | 49.86 | 0.7188 | -0.0496 | -0.0496 | 3.23 | 0.9015 | 1.80 | 14.45 | 10.84 | 417,371.30 | -2.25 | -46.29 | -3.34 | -65.38 | 16.91 | 4.66 | -1.25 | -36.51 | 2.00 | 0.3194 | 0.2654 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
Data as of Nov 21 2024. Currency figures normalised to OptiNose Inc's reporting currency: US Dollar USD
52.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 16.54m | 10.97% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 14.36m | 9.52% |
| Great Point Partners LLCas of 30 Sep 2024 | 12.86m | 8.53% |
| Rosalind Advisors, Inc.as of 30 Sep 2024 | 8.29m | 5.50% |
| Stonepine Capital Management LLCas of 30 Sep 2024 | 5.69m | 3.77% |
| Kingdon Capital Management LLCas of 30 Sep 2024 | 5.60m | 3.71% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 5.00m | 3.32% |
| Bleichroeder LPas of 30 Sep 2024 | 4.05m | 2.68% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.83m | 2.54% |
| Massachusetts Financial Services Co.as of 30 Sep 2024 | 3.08m | 2.04% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
